Identification of colon adenocarcinoma necroptosis subtypes and tumor antigens for the development of mRNA vaccines
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Colon adenocarcinoma (COAD) research identified BAX and IL1B as potential tumor antigens for mRNA vaccines. Two necroptosis subtypes (N1, N2) were found, guiding precision therapy and vaccine development for COAD patients.
Area Of Science
- Oncology
- Immunology
- Genomics
Background
- Colon adenocarcinoma (COAD) presents a significant public health challenge due to high incidence and mortality rates.
- Identifying tumor antigens and necroptosis subtypes is crucial for developing effective mRNA vaccines and personalized treatment strategies for COAD.
Purpose Of The Study
- To identify potential tumor antigens and distinct necroptosis subtypes in COAD.
- To explore the therapeutic potential of identified antigens and subtypes for mRNA vaccine development and precision therapy in COAD patients.
Main Methods
- Utilized The Cancer Genome Atlas and Gene Expression Omnibus for gene expression and clinical data.
- Analyzed necroptosis-related genes (NRGs) using cBioPortal and identified prognostic hub NRGs via Gene Expression Profiling Interactive Analysis 2.
- Performed consensus clustering and Weighted Gene Co-expression Network Analysis (WGCNA) to define necroptosis subtypes and co-expression modules.
Main Results
- Identified BCL-2-associated X protein (BAX) and interleukin 1 beta (IL1B) as key tumor antigens associated with prognosis and immune cell infiltration.
- Distinguished two COAD necroptosis subtypes (N1 and N2) with differential survival and immune marker expression.
- Demonstrated that BAX and IL1B overexpression promote COAD cell necroptosis and enhance CD8+ T cell cytotoxicity.
Conclusions
- BAX and IL1B are promising antigens for developing anti-COAD mRNA vaccines, particularly for the N2 necroptosis subtype.
- The identified necroptosis subtypes and antigens can guide the development of targeted immunotherapies and patient selection for precision treatment in COAD.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.